VANCOUVER, British Columbia (PRWEB) September 17, 2018
Ondine Biomedical, Inc., an innovative medical solutions company, today announced that they have entered into an exclusive agreement with Southmedic, Inc., Barrie, ON, Canada to distribute their first medical solution for the chronic rhinosinusitis (CRS) patient, SurgENTTM, throughout Canada.
The terms of this agreement allow Southmedic to employ their sales and marketing expertise to distribute Ondine’s SurgENT sinus irrigation catheter product across Canada. The distribution agreement may be expanded with additional products in the future.
SurgENT, provides a novel approach to sinus irrigation allowing the surgeon, whether in the office or operating room, to dislodge thick secretions and biofilms within the sinus cavities which traditional irrigation has difficulty removing. Removing these secretions provides instant relief to sinus patients.
"We are pleased to be partnering with Southmedic across Canada to bring our solution to ENT surgeons and sinus patients.” said Michelle Anschuetz, Chief Commercial Officer, Ondine Biomedical, Inc. “The Southmedic team has impressed me not only with their relentless focus on bringing medical innovation to Canadians but also by their dedication to providing quality customer service to the medical community.”
“At Southmedic we take pride in being able to offer our customers innovative and unique surgical and medical products that improve clinical outcomes.” said Steve McCann, SVP of Sales, Southmedic, Inc. “We are very excited about our new partnership with Ondine, another Canadian owned medical device company. This means we are now able to provide a superior solution to surgeons who treat patients suffering with chronic rhinosinusitis.”
About Ondine Biomedical, Inc
Ondine Biomedical Inc. is dedicated to the development of non-antibiotic anti-infective therapies for a broad spectrum of bacterial, viral and fungal infections. Ondine’s platform technology is called photodisinfection, a patented light activated technology that provides rapid antimicrobial efficacy without encouraging antibiotic resistance.
Ondine currently has numerous applications of its photodisinfection technology at various stages of development, including a product that will treat the underlying disease that causes Chronic Rhinosinusitis, named SinuwaveTM. Ondine’s lead product is the MRSAid™ nasal decolonization system which is used to decolonize the nose of all pathogens including methicillin-resistant Staphylococcus aureus (MRSA). Several next-generation products in the hospital-associated infection and CRS markets are currently under development.
About Southmedic, Inc.
Southmedic is a privately owned corporation established in 1983 to provide innovative healthcare products that improve the quality of care with better patient outcomes. Their dynamic Canadian Distribution Division has grown to be one of the largest independent distributors of specialty products focusing on technical support and knowledge that is essential to providing a better healthcare experience.